Navigation Links
ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
Date:8/5/2009

HALIFAX, NS, Aug. 5 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, has signed an agreement with UK-based Scancell Ltd., the operating company of Scancell Holdings Plc (SCLP.PL), which is developing therapeutic cancer and infectious disease vaccines. This research agreement will explore the potential of using IVT's DepoVax(TM) delivery system for Scancell's novel ImmunoBody(R) DNA vaccines.

"Scancell is developing an exciting DNA vaccine technology and we are delighted to enter into this collaboration," remarked Dr. Marc Mansour, vice president of R D at IVT. "Our DepoVax(TM) technology has the potential to better deliver DNA vaccines to draining lymph nodes to produce high levels of immune response using conventional immunization techniques."

"IVT's DepoVax(TM) represents a potentially attractive future delivery system for our ImmunoBody(R) DNA vaccines, especially those for certain infectious diseases where alternative delivery methods such as electroporation may be less suitable." commented David Evans, chairman of Scancell.

DNA-based vaccines have gained popularity due to promising results reported the clinic, their relative ease of manufacture and potential for enhanced stability. There is currently a need for simple alternative methods of delivering DNA vaccines

DepoVax(TM) is a vaccine-enhancement and delivery platform comprised of liposomes, adjuvants and oil. DepoVax(TM) enhances the immunogenicity of antigens in general, and can be used to dramatically enhance the delivery of polynucleotide-based antigens and SiRNA to lymph nodes. IVT has proven its scale-up capabilities at a contract manufacturing plant, making DepoVax(TM) amenable to commercialization.

ImmunoVaccine Technologies continues to strengthen its vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infection disease vaccines. In 2008, Pfizer Animal Health licensed its proprietary vaccine delivery technology for two livestock vaccines. With positive pre-clinical safety data and recent partnerships with LIAI, NIH, Yokohoma City University, Defence Research Development Canada, FIT Biotech, and Immunotope Inc. the value of Depovax(TM) has been significantly enhanced. www.immunovaccine.com.

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody(R) technology platform. Scancell's first cancer vaccine SCIB1 is being developed for the treatment of melanoma and will enter clinical trials using electroporation technology in early 2010.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IVT assumes no responsibility to update forward-looking statements in this press release.


'/>"/>
SOURCE IMMUNOVACCINE TECHNOLOGIES INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
2. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
3. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
4. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
5. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
6. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
7. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
8. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
9. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
10. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
11. ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
Breaking Biology Technology:
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):